STOCK TITAN

Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma

(Neutral)
Tags

Xenetic Biosciences (NASDAQ: XBIO)/b) reported that collaboration partner PeriNess received approval from the Israeli Ministry of Health and an Institutional Review Board for an exploratory, investigator-initiated study of systemic with anti-CD19 CAR T cells in large B-cell lymphoma (LBCL).

The single-center trial at Tel-Aviv Sourasky Medical Center plans to treat 12 LBCL patients with stable or progressive disease using approved anti-CD19 CAR T products plus DNase I, assessing response rates, disease control and overall survival, supported by prior preclinical data showing enhanced CAR T activity.

Loading...
Loading translation...

Positive

  • Israeli Ministry of Health and IRB approval for DNase I + CAR T LBCL study
  • Preclinical models showed improved tumor control, delayed relapse and prolonged survival with DNase I plus CAR T
  • Exploratory trial to evaluate ORR, DOR, DCR and 12‑month OS in 12 LBCL patients

Negative

  • None.

News Market Reaction – XBIO

+2.69% 1.8x vol
6 alerts
+2.69% Session close to close
+8.3% Peak Tracked
-8.8% Trough Tracked
$7.65M Market Cap
1.8x Rel. Volume

In the Jun 4 session, XBIO gained 2.69%, reflecting a moderate positive market reaction. Argus tracked a peak move of +8.3% during that session. Argus tracked a trough of -8.8% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. Trading volume was above average at 1.8x the daily average, suggesting increased trading activity.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details regulatory approval in Israel for an exploratory study combining systemic ...
Analysis

This announcement details regulatory approval in Israel for an exploratory study combining systemic DNase I with anti-CD19 CAR T cells in 12 LBCL patients who have stable or progressive disease before lymphodepletion. It follows a series of updates where DNase I improved CAR-T expansion, tumor control, and survival across models. Historically, similar DNase-focused and earnings news produced modestly positive moves. Key metrics to watch will include ORR at 1 and 3 months and overall survival at 12 months post-infusion.

Key Figures

Planned patient number: 12 LBCL patients DNase I dose: 50-ml IV, 1.0 mg/kg Efficacy timepoints: 1 and 3 months +5 more
8 metrics
Planned patient number 12 LBCL patients Exploratory DNase I + anti-CD19 CAR T study
DNase I dose 50-ml IV, 1.0 mg/kg Given on Days 0, 3, 6, 10, 15 post-CAR T infusion
Efficacy timepoints 1 and 3 months ORR assessment post CAR T infusion
Overall survival follow-up 12 months OS measured 12 months post CAR T infusion
Relapse rate year 1 50–60% LBCL patients relapsing in first year after CAR T
Relapse within 3 months 30–45% Patients relapsing within 3 months post CAR T
PFS with response 60–80% 1-year PFS for partial/complete responders pre–CAR T
PFS stable/progressive 20–30% 1-year PFS for stable/progressive disease at CAR T

Historical Context

5 past events · Latest: Jun 01 (Positive)
Pattern 5 events
Date Event Sentiment 24h Move Catalyst
Jun 01 Preclinical data update Positive +5.1% ASCO 2026 data showing DNase I boosts CAR-T persistence and tumor control.
May 13 Quarterly earnings Positive +5.1% Q1 2026 results with higher royalty revenue and lower net loss.
Apr 22 Conference abstract Positive +1.9% ASCO 2026 abstract acceptance on DNase I to augment CAR-T function.
Mar 13 Full-year earnings Positive +9.5% Full-year 2025 report with royalty growth and DNase program progress.
Dec 11 Corporate governance Neutral +0.8% Adjourned 2025 annual meeting due to lack of quorum.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent XBIO news and earnings items have generally been followed by modestly positive 1-day moves, suggesting the market has often rewarded DNase I and CAR-T related progress.

Recent Company History

Over the last six months, Xenetic has steadily highlighted progress around its DNase I immuno-oncology platform. In March 2026, full-year 2025 results showed growing royalty revenue and continued DNase investment, followed by Q1 2026-05-13 earnings with higher royalties and reduced losses. Multiple ASCO-related announcements in April–June 2026 showcased preclinical data where DNase I enhanced CAR-T expansion and tumor control. These updates, along with corporate governance news in December 2025, generally coincided with positive price reactions, framing today’s clinical-study approval as a continuation of that DNase-focused trajectory.

Key Terms

dnase i, car t cells, large b cell lymphoma, objective response rate, +4 more
8 terms
dnase i medical
"systemic recombinant human DNase I in combination with anti-CD19 CAR T cells"
DNase I is an enzyme that cuts DNA strands into smaller pieces, like molecular scissors that break long threads into shorter fragments. For investors, DNase I matters because it is used in medical treatments, laboratory tests and manufacturing processes; changes in clinical trial results, regulatory approval, patent control, or production capacity can affect companies’ revenues and costs in biotech, diagnostics and contract manufacturing.
car t cells medical
"combination systemic DNase I with anti-CD19 CAR T Cells in large B cell lymphoma"
CAR T cells are a personalized medical treatment made by taking a person’s own immune cells (T cells) and genetically reprogramming them to spot and attack specific diseased cells, like training guard dogs to recognize a particular scent. They matter to investors because they can deliver dramatic clinical benefits and large market opportunity, but also carry high development and manufacturing costs, regulatory hurdles, and safety risks that affect commercial success.
large b cell lymphoma medical
"anti-CD19 CAR T Cells in large B cell lymphoma (LBCL) patients"
Large B‑cell lymphoma is an aggressive cancer of a type of white blood cell (B lymphocytes) that normally helps fight infections; the cells grow and divide uncontrollably, forming tumors in lymph nodes or other organs. Investors pay attention because diagnosis, treatment advances, clinical trial results, regulatory approvals, and cost or uptake of new therapies can sharply affect drugmakers’ revenues, hospital spending and the valuation of companies developing targeted medicines or diagnostics.
objective response rate medical
"Clinical efficacy is intended to be evaluated by the Objective Response Rate (ORR)"
The objective response rate (ORR) is the percentage of patients in a clinical trial whose tumors measurably shrink or disappear according to preset rules. Investors use it as a quick, objective signal of a drug’s ability to produce a clear treatment effect—like counting how many plants visibly respond after applying a new fertilizer—and higher ORR can improve odds of regulatory approval, commercial success, and company valuation.
duration of response medical
"evaluated by the Objective Response Rate (ORR) at 1 and 3 months post CAR T infusion, duration of response (DOR)"
Duration of response is the length of time a patient’s condition stays improved after a treatment until it starts to worsen again; think of it as how long a freshly charged battery continues to power a device. For investors, longer duration of response implies a treatment provides sustained benefit, which can boost a drug’s commercial value, support stronger regulatory labeling and payer coverage, and reduce the need for additional therapies.
disease control rate medical
"duration of response (DOR), disease control rate (DCR) and overall survival (OS)"
The disease control rate is the share of patients in a clinical trial whose cancer or condition either shrinks or stops getting worse for a specified period after treatment. Think of it like the percentage of people for whom a treatment hits pause or nudges back the problem rather than letting it progress; higher rates suggest the therapy can meaningfully limit disease, which matters to investors assessing a drug’s potential efficacy and commercial value.
overall survival medical
"disease control rate (DCR) and overall survival (OS) at 12 months post CAR T cells infusion"
Overall survival is the average or median length of time patients remain alive after starting a treatment or entering a clinical study, measured regardless of cause of death. Investors care because it is a clear, hard measure of a therapy’s real-world benefit — like timing how long a new battery actually runs — and strong improvements in overall survival can drive regulatory approval, market adoption and revenue potential.
neutrophil extracellular traps medical
"accumulation of cell-free chromatin and neutrophil extracellular traps (NETs) within the tumor microenvironment"
Neutrophil extracellular traps (NETs) are web-like strands of DNA and proteins expelled by certain white blood cells to trap and neutralize invading germs, like a spider spinning a sticky web to catch insects. For investors, NETs matter because they are linked to inflammation, blood clots and chronic disease, making them potential targets for new diagnostics and therapies and a factor in safety and efficacy assessments for drug and device development.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Company evaluating systemic recombinant human DNase I in combination with anti-CD19 CAR T cells targeting lymphoma patients in stable or progressive disease at lymphodepletion

Company reported strong positive preclinical results demonstrating significantly enhanced anti-tumor activity of anti-CD-19 CAR T cells when combined with DNase I in multiple preclinical models of hematologic cancers

Investigator initiated study to be conducted at Tel-Aviv Sourasky Medical Center ("Sourasky Center")

FRAMINGHAM, MA / ACCESS Newswire / June 4, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its collaboration partner, PeriNess Ltd. (PeriNess), has informed the Company that it received formal approval from the Israeli Ministry of Health and the respective Institutional Review Board to conduct an exploratory clinical study of a combination systemic DNase I with anti-CD19 CAR T Cells in large B cell lymphoma (LBCL) patients. This approval follows positive preclinical results that demonstrated significant improvement of CAR T cell expansion and persistence and functionality when combined with DNase I. This combination therapy resulted in improved tumor control, delayed relapse and prolonged survival across multiple preclinical models of leukemia and lymphoma.

Under the approved clinical study protocol, 12 LBCL patients with stable or progressive disease prior to lymphodepletion therapy are intended to be treated with CAR T cells targeting CD19 (tisagenlecleucel, axicabtagene ciloleucel, or lisocabtagene maraleucel) in combination with DNase I (50-ml IV infusion dose, 1.0 mg/kg IV on Days 0,3,6,10 and 15 after CAR T cells infusion). Clinical efficacy is intended to be evaluated by the Objective Response Rate (ORR) at 1 and 3 months post CAR T infusion, duration of response (DOR), disease control rate (DCR) and overall survival (OS) at 12 months post CAR T cells infusion. We believe the study has the potential for a translational component with a complex assessment of biomarker response and analysis of anti-CD19 CAR T expansion and persistence.

Dr. Ron Ram, Professor of Medicine and Head of the Bone Marrow Transplantation Unit at the Sourasky Center, has initiated the study as the principal investigator and all work is intended to be conducted at Sourasky Center in Israel.

"Progression of LBCL is the major obstacle for the success of CAR T therapies, with approximately 50-60% of the patients relapsing in the first year, and approximately 30-45% within 3 months after CAR T infusion, depending on the CAR T product used. While patients with partial or complete response before CAR T infusion have a 1-year progression free survival of approximately 60-80%, those with stable or progressive disease at the time of CAR T infusion have a dismal 1-year progression free survival of approximately 20-30%," commented Dr. Ram "Preclinical data generated over the last few years confirms that accumulation of cell-free chromatin and neutrophil extracellular traps (NETs) within the tumor microenvironment represents a general mechanism of CAR T-cell dysfunction through induction of exhaustion, immunosuppression and impaired expansion and this mechanism is targetable by DNase I. The goal of this clinical study is to improve clinical response by administering DNase I to abrogate the negative effects of cell-free chromatin and NETs on the performance of immune system and CAR T cells."

Alexey Stepanov, PhD, Institute Investigator at The Scripps Research Institute and a member of Xenetic's Scientific Steering Committee, added, "CAR T cell treatment induces intensive tumor-cell death and inflammation within the tumor over a short period of time, resulting in massive release of cell-free chromatin and neutrophil extracellular traps (NETs) into the tumor microenvironment. This extracellular DNA burden acts as a major stress factor that accelerates CAR T cell dysfunction and exhaustion, creating a potent negative feedback loop that limits durable efficacy. DNase I disrupts this loop by degrading cell-free chromatin and NETs, thereby improving CAR T cell fitness, preserving cytotoxicity and functional persistence and reducing exhaustion markers, including PD-1, LAG-3, and TIM-3. In our preclinical models, these effects were associated with more durable tumor control following repeated tumor re-challenge, with no tumor regrowth observed in DNase I-treated animals under conditions where tumor progression occurred in the control group. Importantly, unlike conventional strategies that seek to improve CAR T cells primarily through additional cell engineering, our approach is designed to improve the battlefield itself by removing key extracellular barriers to CAR T cell function. We believe the planned study at Tel Aviv Sourasky Medical Center is particularly meaningful given the institution's longstanding leadership in CAR T-cell therapy and immuno-oncology innovation, both in Israel and internationally. As a pioneer in the development, clinical validation and early adoption of advanced cellular therapies, Sourasky Center combines elite clinical expertise, cutting-edge translational research infrastructure and a proven ability to rapidly translate scientific discoveries into innovative patient treatments, making it an ideal institution to lead this exploratory clinical study."

About Tel Aviv Sourasky Medical Center

The Tel Aviv Sourasky University Medical Center is the second-largest hospital in Israel. It provides healthcare services to approximately 4 million residents of the Tel Aviv metropolitan area (Gush Dan) and serves citizens from all over the country. The Tel Aviv Medical Center is a municipal-government hospital that comprises four hospitals: Ichilov General Hospital, Lis Maternity and Women's Hospital, Dana-Dwek Children's Hospital, and the Ida Sourasky Rehabilitation Hospital. In 2022, the Sylvan Adams Emergency Medicine Hospital was inaugurated. At the end of 2023, rehabilitation services were significantly expanded with the opening of BeShilam - the Rehabilitation Hospital for War Casualties.

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company's proprietary DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.

For more information, please visit the Company's website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," "remain," "focus", "confidence in", "potential", "continues", "warrants", and other words of similar meaning, including, but not limited to, all statements regarding planned treatments under clinical study protocol 12 LBCL and intended evaluations of the clinical efficacy thereof, the Company's belief that clinical study protocol 12LBCL has the potential for a translational component with a complex assessment of biomarker response and analysis anti-CD19 CAR T expansion and persistence, where work related to the study is intended to be conducted,, our focus on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, the DNase platform improving outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, and our focus on advancing our systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors. Any forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements, or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual activities, performance, achievements, or results to differ materially from such plans, estimates or expectations include, among others, (1) unexpected costs, charges or expenses resulting from our manufacturing and collaboration agreements; (2) unexpected costs, charges or expenses resulting from the licensing of the DNase platform; (3) uncertainty of the expected financial performance of the Company following the licensing of the DNase platform; (4) failure to realize the anticipated potential of the DNase or PolyXen technologies; (5) the ability of the Company to obtain funding and implement its business strategy; (6) risks and uncertainties as to the outcome and timing of the strategic review process being conducted by the Board and a special independent committee thereof, including the possibility that the Board may decide not to undertake a strategic alternative following the evaluation process, the Company's inability to consummate any proposed strategic alternative resulting from the review due to, among other things, market, regulatory and other factors, the potential for disruption to our business resulting from the review process, and potential adverse effects on the Company's stock price from the announcement, suspension or consummation of the evaluation process and the results thereof, as well as risks and uncertainties related to the potential impacts of consummation of a strategic transaction on the Company's current business operations, anticipated business strategy and product development plans; and (7) other risk factors as detailed from time to time in the Company's reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues, and geopolitical events, such as the conflicts in Ukraine and in the Middle East, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions, litigation, and shareholder activism, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.

Contact:

JTC Team, LLC
Jenene Thomas
(908) 824-0775
xbio@jtcir.com

SOURCE: Xenetic Biosciences, Inc.



View the original press release on ACCESS Newswire

FAQ

What did Xenetic Biosciences (NASDAQ: XBIO) announce on June 4, 2026 about its DNase I program?

Xenetic announced regulatory approval for an exploratory study combining DNase I with anti-CD19 CAR T cells in LBCL. According to Xenetic, Israel’s Ministry of Health and an Institutional Review Board cleared the investigator-initiated trial at Tel-Aviv Sourasky Medical Center.

What is the design of the DNase I plus anti-CD19 CAR T study in LBCL for XBIO?

The study plans to treat 12 LBCL patients with stable or progressive disease before lymphodepletion. According to Xenetic, patients will receive approved anti-CD19 CAR T products plus systemic DNase I, with dosing on Days 0, 3, 6, 10 and 15 after infusion.

Which endpoints will the XBIO-linked DNase I and CAR T clinical study evaluate?

The trial will primarily assess objective response rate at 1 and 3 months after CAR T infusion. According to Xenetic, additional endpoints include duration of response, disease control rate and overall survival at 12 months, plus translational biomarker analyses of CAR T expansion and persistence.

What preclinical results support Xenetic’s DNase I combination with anti-CD19 CAR T cells?

Preclinical models showed DNase I improved CAR T expansion, persistence and tumor control while delaying relapse. According to Xenetic, DNase I degraded cell-free chromatin and NETs, reducing CAR T exhaustion markers and yielding prolonged survival versus control animals in multiple leukemia and lymphoma models.

Which CAR T products are included in the DNase I combination study associated with XBIO?

The protocol allows tisagenlecleucel, axicabtagene ciloleucel, or lisocabtagene maraleucel as anti-CD19 CAR T options. According to Xenetic, these commercial CAR T therapies will be combined with systemic DNase I to treat 12 large B-cell lymphoma patients at Sourasky Center.